#USA #New York #Anixa Biosciences #Breast Cancer Vaccine #Ovarian CAR-T

Anixa Biosciences to Present Innovative Cancer Therapies at Major Healthcare Conference

Anixa Biosciences, Inc., a prominent player in the biotechnology sector focused on cancer prevention and treatment, is set to present at the 2026 Cantor Fitzgerald Global Healthcare Conference from September 9 to 11 in New York City. This conference will highlight the firm’s groundbreaking work, particularly in its breast cancer vaccine and ovarian cancer CAR-T therapy, advancing the frontier of cancer treatment.

Significant Clinical Progress

In recent developments, Anixa has shared the final data from the Phase 1 clinical trial of its breast cancer vaccine, conducted in collaboration with the Cleveland Clinic. Encouragingly, the trial met all primary endpoints, demonstrating safety and efficacy with 74% of participants exhibiting immune responses defined by the trial's protocols. This promising result paves the way for preparations for a Phase 2 clinical trial.

Dr. Amit Kumar, Chairman and CEO of Anixa, expressed optimism about the future of cancer vaccines, especially after recent presentations by major pharmaceutical companies Merck and Moderna regarding similar technologies. These advancements signal an increasing recognition of cancer vaccines as a vital part of oncological care. Anixa is now gearing up to transition its vaccine into the next phase of clinical trials, furthering its mission to combat breast cancer effectively.

Advancements in Ovarian Cancer Treatments

In addition to the breast cancer vaccine, Anixa is also making strides with its ovarian cancer CAR-T therapy, known as lira-cel. This innovative treatment is being developed in collaboration with the Moffitt Cancer Center, focusing on patients suffering from recurrent and resistant forms of ovarian cancer. The therapy is currently in a Phase 1 clinical trial, where it has reached the fifth and highest dosing cohort thus far. Notably, no dose-limiting toxicities have been reported, and four patients have achieved survival beyond one year, with the longest survival time around 28 months.

Mike Catelani, Anixa's President, COO, and CFO, remarked, “This is an exciting time for Anixa, with our breast cancer vaccine advancing toward Phase 2 and our ovarian cancer CAR-T program now dosing at the highest level evaluated in the trial.” Such outcomes are a testament to the company’s commitment to revolutionizing cancer therapies and improving patient outcomes.

Event Details

Anixa will host a presentation on September 11, 2026, at 8:00 AM ET, at the Waldorf Astoria in New York. This will be an excellent opportunity for investors, healthcare professionals, and the media to meet with Anixa's management and discuss the latest developments in their clinical trials and partnerships with renowned research institutions.

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc. is dedicated to innovating cancer therapies through collaboration with leading research institutions. Their portfolio includes novel treatments that target ovarian cancer and breast cancer, leveraging cutting-edge technologies like chimeric endocrine receptor-T cell (CER-T) therapy. By focusing on vaccines that harness the immune system against cancers, Anixa aims to address large unmet needs in oncology and improve the quality of life for patients worldwide. For more information, visit Anixa and follow them on social media platforms to stay updated on their progress.

In conclusion, Anixa's participation in the 2026 Cantor Fitzgerald Global Healthcare Conference will not only spotlight their recent advancements but also reaffirm their pivotal role in the ongoing fight against cancer. With a solid foundation in biotech innovation and a robust clinical pipeline, Anixa is poised to make substantial contributions to the field of oncology in the years to come.